$14.61
5.62% yesterday
NYSE, Aug 21, 10:00 pm CET
ISIN
US6031701013
Symbol
MLYS

Mineralys Therapeutics Stock price

$14.61
+0.99 7.27% 1M
+5.05 52.82% 6M
+2.30 18.68% YTD
+3.47 31.15% 1Y
-3.83 20.77% 3Y
-3.83 20.77% 5Y
-3.83 20.77% 10Y
-3.83 20.77% 20Y
NYSE, Closing price Thu, Aug 21 2025
-0.87 5.62%
ISIN
US6031701013
Symbol
MLYS
Industry

Key metrics

Basic
Market capitalization
$1.0b
Enterprise Value
$701.3m
Net debt
positive
Cash
$324.9m
Shares outstanding
65.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.3
Financial Health
Equity Ratio
92.9%
Return on Equity
-93.0%
ROCE
-64.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-203.0m | $-204.7m
EBIT
$-203.1m | $-191.8m
Net Income
$-190.8m | $-193.5m
Free Cash Flow
$-193.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-51.2% | -6.4%
EBIT
-51.2% | 0.3%
Net Income
-59.3% | -8.8%
Free Cash Flow
-99.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.9
FCF per Share
$-2.9
Short interest
14.2%
Employees
51
Rev per Employee
$0.0
Show more

Is Mineralys Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,014 stocks worldwide.

Mineralys Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Mineralys Therapeutics forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Mineralys Therapeutics forecast:

Buy
87%
Hold
13%

Financial data from Mineralys Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 28 28
55% 55%
-
- Research and Development Expense 175 175
50% 50%
-
-203 -203
51% 51%
-
- Depreciation and Amortization 0.05 0.05
150% 150%
-
EBIT (Operating Income) EBIT -203 -203
51% 51%
-
Net Profit -191 -191
59% 59%
-

In millions USD.

Don't miss a Thing! We will send you all news about Mineralys Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mineralys Therapeutics Stock News

Neutral
Seeking Alpha
9 days ago
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Adam Scott Levy - CFO & Secretary Eric Warren - Chief Commercial Officer Jon Congleton - President, CEO & Director Daniel Ferry - Managing Director, Lifesci Advisors, LLC Conference Call Participants Alice Jennifer Nettleton - BofA Securities, Research Division Jayed Momi...
Neutral
GlobeNewsWire
9 days ago
– Presented and published the positive results from both the Launch-HTN and Advance-HTN pivotal trials at scientific meetings and in JAMA and NEJM – – Pre-NDA meeting scheduled to take place in 4Q 2025 – – Explore-CKD Phase 2 trial successfully achieved statistical significance in reduction of systolic BP and UACR, and demonstrated a favorable safety profile – – Explore-OSA Phase 2 trial in OSA...
Neutral
GlobeNewsWire
17 days ago
RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as hypertensive nephropathy, obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the ...
More Mineralys Therapeutics News

Company Profile

Mineralys Therapeutics, Inc. s a clinical-stage biopharmaceutical company engaged in developing medicines to target disease, driven by abnormally elevated aldosterone. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Head office United States
CEO Jon Congleton
Employees 51
Founded 2019
Website mineralystx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today